Biora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:33 pm
Share
Biora Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.002 million compared to USD 0.104 million a year ago. Net loss was USD 17.81 million compared to USD 5.51 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 0.81 a year ago. Diluted loss per share from continuing operations was USD 1.47 compared to USD 0.81 a year ago. Basic loss per share was USD 1.47 compared to USD 0.75 a year ago. Diluted loss per share was USD 1.47 compared to USD 0.75 a year ago.
For the six months, sales was USD 0.004 million compared to USD 0.211 million a year ago. Net loss was USD 35.25 million compared to USD 19.32 million a year ago. Basic loss per share from continuing operations was USD 3.01 compared to USD 2.79 a year ago. Diluted loss per share from continuing operations was USD 3.01 compared to USD 2.79 a year ago. Basic loss per share was USD 3.01 compared to USD 2.63 a year ago. Diluted loss per share was USD 3.01 compared to USD 2.63 a year ago.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Companyâs pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
BIORA THERAPEUTICS, INC. 
